A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma
Lists
Only you see this
Abstract
CD95 pathway inhibition in combination with rRT is an innovative concept with clinical efficacy. It warrants further clinical development. CD95L promoter methylation in the tumor may be developed as a biomarker.
BibTeX
@inproceedings{wick2014phase,
author = {Wolfgang Wick and Harald Fricke and Klaus Junge and Grigory Kobyakov and Tobias Martens and Oliver Heese and Benedikt Wiestler and Maximilian G. Schliesser and Andreas von Deimling and Josef Pichler and E R Vetlova and Inga Harting and Jürgen Debus and Christian Hartmann and Claudia Kunz and Michael Platten and Martin Bendszus and Stephanie E. Combs},
title = {{A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma}},
booktitle = {Clinical},
year = {2014},
doi = {10.1158/1078-0432.ccr-14-0951-t},
}Loading related content...